IQVIA HoldingsLTS:0JDM +5.93%87 EV-to-FCF is 22.69 as of Jul. 02, 2026, which is 33% below its 10-year median of 34.01. GuruFocus rates LTS:0JDM with a GF Score™ of 87/100 and a GF Value™ of $248.34 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 51.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, IQVIA Holdings's Enterprise Value is $48,004 Mil.
IQVIA Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $2,116 Mil. Therefore, IQVIA Holdings's EV-to-FCF for today is 22.69.
The historical rank and industry rank for IQVIA Holdings's EV-to-FCF or its related term are showing as below:
LTS:0JDM'
s EV-to-FCF Range Over the Past 10 Years
Min: 17.08 Med: 34.01 Max: 64.49
Current: 21.9
During the past 13 years, the highest EV-to-FCF of IQVIA Holdings was 64.49. The lowest was 17.08. And the median was 34.01.
LTS:0JDM's EV-to-FCF is ranked better than 51.55% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.51
vs LTS:0JDM: 21.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IQVIA Holdings's PE Ratio (TTM) for today is calculated as:
IQVIA Holdings's share price for today is $203.41.
IQVIA Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
IQVIA Holdings EV-to-FCF Related Terms
IQVIA Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IQVIA Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's EV-to-FCF falls into.
IQVIA Holdings's current Enterprise Value is $48,004 Mil.
IQVIA Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,116 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (LTS:0JDM) has a EV-to-FCF of 22.69 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on IQVIA Holdings and its competitors. This is 33% below median its historical median of 34.01. Over the past decade, IQVIA Holdings' EV-to-FCF has ranged from 17.08 to 64.49. According to the industry distribution chart, IQVIA Holdings ranks #47 out of 97 companies in the Medical Diagnostics & Research industry, placing it in the top 48.5%.
Is IQVIA Holdings' EV-to-FCF too high?
IQVIA Holdings' current EV-to-FCF of 22.69 is 33% below median its 10-year median of 34.01. Over the past 10 years, this metric has ranged from a low of 17.08 to a high of 64.49. The Medical Diagnostics & Research industry median EV-to-FCF is 22.51. IQVIA Holdings' value of 22.69 is 0.8% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #47 out of 97 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' EV-to-FCF compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #47 out of 97 companies for EV-to-FCF. This puts IQVIA Holdings in the upper half of its industry. The industry median EV-to-FCF is 22.51. IQVIA Holdings' value of 22.69 is 0.8% above this benchmark. Historically, IQVIA Holdings' own EV-to-FCF has ranged from 17.08 to 64.49 over the past decade. While the company's 10-year median is 34.01 vs. the industry median of 22.51, IQVIA Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.51, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current EV-to-FCF of 22.69 is 0.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current EV-to-FCF is 22.69, which is 33% below median its own 10-year median of 34.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $248.34, compared to a current price of $203.41 — trading 18.1% below its estimated fair value. The current EV-to-FCF is 22.69, which is 33% below median its 10-year median of 34.01 and 0.8% above the Medical Diagnostics & Research industry median of 22.51. IQVIA Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current EV-to-FCF is 22.69 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $203.41 is trading 18.1% below its estimated GF Value™ of $248.34.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for LTS:0JDM:
EV-to-FCF: 22.69 (33% below median its 10-year median of 34.01)
GF Value™: $248.34 vs. price of $203.41 (18.1% below fair value)
Industry Position: 0.8% above the Medical Diagnostics & Research median (#47 of 97)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
87GF Score
Get the complete analysis for LTS:0JDM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
